HC Wainwright Has Lowered Expectations for OnKure Therapeutics (NASDAQ:OKUR) Stock Price

OnKure Therapeutics (NASDAQ:OKUR) had its price target cut by stock analysts at HC Wainwright from $40.00 to $34.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Other equities analysts also recently issued research reports about the company. Oppenheimer dropped their price objective on OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 11th. Leerink Partnrs upgraded shares of OnKure Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Finally, Leerink Partners started coverage on shares of OnKure Therapeutics in a research note on Thursday, December 5th. They issued an “outperform” rating and a $33.00 price objective for the company. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, OnKure Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $32.33.

OnKure Therapeutics Stock Performance

OKUR stock opened at $4.82 on Tuesday. The stock has a market capitalization of $64.76 million, a PE ratio of -0.40 and a beta of 0.28. The stock has a fifty day simple moving average of $5.66. OnKure Therapeutics has a 1-year low of $4.45 and a 1-year high of $20.00.

OnKure Therapeutics (NASDAQ:OKUR) last issued its quarterly earnings results on Monday, March 10th. The company reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.51). As a group, equities research analysts forecast that OnKure Therapeutics will post -4.05 earnings per share for the current year.

Institutional Investors Weigh In On OnKure Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Barclays PLC purchased a new position in OnKure Therapeutics during the fourth quarter valued at approximately $75,000. OMERS ADMINISTRATION Corp bought a new position in OnKure Therapeutics in the 4th quarter valued at $104,000. Walleye Capital LLC purchased a new position in shares of OnKure Therapeutics during the 4th quarter valued at $116,000. Two Sigma Advisers LP bought a new position in shares of OnKure Therapeutics in the fourth quarter worth $122,000. Finally, Shay Capital LLC purchased a new stake in shares of OnKure Therapeutics in the fourth quarter worth $129,000. 90.98% of the stock is owned by hedge funds and other institutional investors.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.